Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H17NO |
| Molecular Weight | 179.2588 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]([C@@H](O)C1=CC=CC=C1)N(C)C
InChI
InChIKey=FMCGSUUBYTWNDP-MWLCHTKSSA-N
InChI=1S/C11H17NO/c1-9(12(2)3)11(13)10-7-5-4-6-8-10/h4-9,11,13H,1-3H3/t9-,11-/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9681334
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1310.12
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9681334
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1310.12
Methylephedrine is one of the ephedra alkaloids that is found in varying amounts in different species of the plant genus Ephedra. Methylephedrine is a popular antitussive, bronchodilator, analgesic, antipyretic, and widely used mixed with other drugs in preparations for treatment of the common cold. N-Methylephedrine, its salts, optical isomers, and salts of optical isomers are in FDA list of Exempt chemical mixtures.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Histamine receptors |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Sanwa Approved UseIt is usually used in the treatment of cough associated with diseases such as bronchial asthma, cold, acute or chronic bronchitis, pulmonary tuberculosis, and upper airway inflammation. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Comparative studies on a broncholytic and circulatory effect of methylephedrine and ephedrine]. | 1970 Feb 15 |
|
| [Broncholytic effect of methylephedrine in acute study]. | 1974 Sep |
|
| [Caffeine-11C, ephedrine-11C and methylephedrine-11C: Synthesis and distribution in mice (author's transl)]. | 1978 Aug |
|
| Methylephedrine concentrations in blood and urine specimens. | 1998 Jul-Aug |
Patents
Sample Use Guides
Take 0.25-0.5 g (25-50 mg of the active ingredient) at a time, 3 times daily
Route of Administration:
Oral
l-MEP inhibited the twitch response at high concentrations (3 x 10(-5)-10(-3) M). On the other hand, d-MEP showed the potentiation of twitch response, and competitively antagonized the twitch-inhibitory effect of clonidine (10(-9)-10(-6) M) with the pA2 value of 4.3 in the presence of prazosin.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
102023
Created by
admin on Sat Dec 16 05:25:20 GMT 2023 , Edited by admin on Sat Dec 16 05:25:20 GMT 2023
|
PRIMARY | |||
|
42151-56-4
Created by
admin on Sat Dec 16 05:25:20 GMT 2023 , Edited by admin on Sat Dec 16 05:25:20 GMT 2023
|
PRIMARY | |||
|
VP306Z33KI
Created by
admin on Sat Dec 16 05:25:20 GMT 2023 , Edited by admin on Sat Dec 16 05:25:20 GMT 2023
|
PRIMARY | |||
|
DTXSID20962313
Created by
admin on Sat Dec 16 05:25:20 GMT 2023 , Edited by admin on Sat Dec 16 05:25:20 GMT 2023
|
PRIMARY | |||
|
m7410
Created by
admin on Sat Dec 16 05:25:20 GMT 2023 , Edited by admin on Sat Dec 16 05:25:20 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD
